Considerations in sirolimus use in the early and late post-transplant periods.
Sirolimus is an antiproliferative immunosuppressive agent that inhibits the mammalian target of rapamycin. It is highly effective in preventing acute renal allograft rejection and can be used with either calcineurin inhibitors, antimetabolites or corticosteroids. Early studies in renal transplantation have provided insight into optimal dosing strategies of sirolimus and of concomitant immunosuppressive agents. Familiarity with the adverse effect profile of sirolimus and pharmacokinetic and dynamic interactions with other immunosuppressive agents allows for earlier recognition and better management of sirolimus-related complications. The role of sirolimus in preserving long-term renal function, post-transplant malignancies and in prevention of atherosclerosis is currently being considered.
Patel
Samir J
SJ
The Methodist Hospital, Department of Pharmacy, 6565 Fannin St. MB1-056, Houston, TX 77030, USA. spatel2@tmhs.org
Elliott
Erin N
EN
Knight
Richard J
RJ
Gaber
Lillian W
LW
Gaber
A Osama
AO
D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000517:prevention & control*; D016030:Kidney Transplantation / Q000009:adverse effects; D011184:Postoperative Period; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016559:Tacrolimus / Q000008:administration & dosage; D013997:Time Factors
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D020123:Sirolimus; D016559:Tacrolimus